Their results showed a clear difference in polysialylated and hyposialylated forms of serum NCAM and revealed that NCAM is hyposialylated in patient serum samples, suggesting changes of NCAM-sialysation to a potential serum biomarker for GNE myopathy [74]. The gene discussed is NCAM1; the disease is Distal myopathy, Nonaka type.